Trial · NCT01902290
Results by group77
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 77
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24 | Placebo | -0.815 | Standard Error 0.073 | score on a scale | |
| Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Score at Week 24 | Brodalumab 210 mg | -0.865 | Standard Error 0.074 | score on a scale | |
| Asthma Exacerbation Rate | Placebo | 0.57 | exacerbations per subject-year | ||
| Asthma Exacerbation Rate | Brodalumab 210 mg | 0.81 | exacerbations per subject-year | ||
| Change From Baseline in ACQ Composite Score at Week 24 in ICS+LABA Subpopulation | Placebo | -0.793 | Standard Error 0.084 | score on a scale | |
| Change From Baseline in ACQ Composite Score at Week 24 in ICS+LABA Subpopulation | Brodalumab 210 mg | -0.831 | Standard Error 0.088 | score on a scale | |
| Asthma Exacerbation Rate in ICS+LABA Subpopulation | Placebo | 0.60 | exacerbations per subject-year | ||
| Asthma Exacerbation Rate in ICS+LABA Subpopulation | Brodalumab 210 mg | 0.89 | exacerbations per subject-year | ||
| Change From Baseline in Daily Asthma Symptom Score (7-day Average Score) | Placebo | -0.397 | Standard Error 0.042 | score on a scale | |
| Change From Baseline in Daily Asthma Symptom Score (7-day Average Score) | Brodalumab 210 mg | -0.443 | Standard Error 0.043 | score on a scale | |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) | Placebo | 0.207 | Standard Error 0.045 | L/s | |
| Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) | Brodalumab 210 mg | 0.237 | Standard Error 0.046 | L/s | |
| Change From Baseline in Daily Rescue Short-acting Beta-agonist Use | Placebo | -1.359 | Standard Error 0.243 | puffs | |
| Change From Baseline in Daily Rescue Short-acting Beta-agonist Use | Brodalumab 210 mg | -1.231 | Standard Error 0.246 | puffs | |
| Time to First Asthma Exacerbation | Placebo | 20.1 | percentage of participants | ||
| Time to First Asthma Exacerbation | Brodalumab 210 mg | 23.9 | percentage of participants | ||
| Number of Participants Who Experienced an Asthma Exacerbation | Placebo | 41 | Participants | ||
| Number of Participants Who Experienced an Asthma Exacerbation | Brodalumab 210 mg | 49 | Participants | ||
| Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall Score | Placebo | 0.804 | Standard Error 0.085 | score on a scale | |
| Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Overall Score | Brodalumab 210 mg | 0.803 | Standard Error 0.087 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01902290/results